OSI Hires Transgenomic to Analyze Genetic Mutations for Cancer | GenomeWeb
NEW YORK (GenomeWeb News) — Transgenomic today said it will analyze cancer pathway genes for OSI Pharmaceuticals using a high-throughput methodology it developed for characterizing gene variants in malignant tumors.
Transgenomic said its high-throughput scanning offers forward and reverse Sanger sequencing and variant annotation to detect the mutations, and that it will be used to help OSI in its cancer drug-development programs.
Financial terms of the agreement were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.